Trial Profile
EVALUATION OF CLINICAL RESPONSE TO RITUXIMAB TREATMENT IN PATIENTS WITH ACQUIRED AUTOIMMUNE RECURRENT THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Jul 2014
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Thrombotic thrombocytopenic purpura
- Focus Therapeutic Use
- 07 Jul 2014 New trial record